Dr Craig Gedye
Conjoint Associate Professor
School of Medicine and Public Health
Career Summary
Biography
My research focuses on complexity in cancer, with a particular interest in understanding "intratumoural heterogeneity". In every patient, every cancer cell is a bit different to every other cancer cell. Some cancer cells seem to be able to spread and cause trouble; others are less aggressive. What determines these differences? Can we exploit them to target cancer cells that are behaving differently?
Between different patients, cancers that come from the same organ can behave completely differently, and treatments that help one patient fail the next. Why is this? Why does a cancer lie dormant, then come back? Why does treatment not work in some patients, or work for a time, then fail?
These questions are incredibly important, as we seek to find the treatments that work best for each individual patient. We will do this by using existing treatments more cleverly, as well as by discovering new treatments.
Qualifications
- PhD (Medicine Denistry & Health Sciences), University of Melbourne
- Bachelor of Science (Chemistry)(Honours), University of Canterbury - New Zealand
- Bachelor of Medicine, Bachelor of Surgery, University of Otago - New Zealand
Keywords
- Biobanking
- Cancer
- Cancer biology
- Cancer immunotherapy
- Cancer stem cells
- Cell biology
- Clinical trials
- Epigenetic heterogeneity
- Glioblastoma
- Medical oncology
- Melanoma
- Phenotypic plasticity
- Prostate cancer
- Renal cell carcinoma
- Urothelial cancer
Professional Experience
Professional appointment
Dates | Title | Organisation / Department |
---|---|---|
28/5/2016 - 30/11/2017 | Conjoint Senior Lecturer | The University of Newcastle - Faculty of Health and Medicine Australia |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Chapter (1 outputs)
Year | Citation | Altmetrics | Link |
---|---|---|---|
2021 | Gedye C, 'Cancer Heterogeneity', The Basic Science of Oncology, Sixth Edition, McGraw-Hill Education / Medical, Chicago (2021) |
Journal article (87 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2024 |
Conduit C, Davis ID, Goh JC, Kichenadasse G, Gurney H, Harris CA, et al., 'A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma', BJU International, 133 57-67 (2024) [C1] Objective: To evaluate the efficacy of sequential treatment with ipilimumab and nivolumab following progression on nivolumab monotherapy in individuals with advanced, non-clear-ce... [more] Objective: To evaluate the efficacy of sequential treatment with ipilimumab and nivolumab following progression on nivolumab monotherapy in individuals with advanced, non-clear-cell renal cell carcinoma (nccRCC). Materials and Methods: UNISoN (ANZUP1602; NCT03177239) was an open-label, single-arm, phase 2 clinical trial that recruited adults with immunotherapy-naïve, advanced nccRCC. Participants received nivolumab 240 mg i.v. two-weekly for up to 12 months (Part 1), followed by sequential addition of ipilimumab 1 mg/kg three-weekly for four doses to nivolumab if disease progression occurred during treatment (Part 2). The primary endpoint was objective tumour response rate (OTRR) and secondary endpoints included duration of response (DOR), progression-free (PFS) and overall survival (OS), and toxicity (treatment-related adverse events). Results: A total of 83 participants were eligible for Part 1, including people with papillary (37/83, 45%), chromophobe (15/83, 18%) and other nccRCC subtypes (31/83, 37%); 41 participants enrolled in Part 2. The median (range) follow-up was 22 (16¿30) months. In Part 1, the OTRR was 16.9% (95% confidence interval [CI] 9.5¿26.7), the median DOR was 20.7 months (95% CI 3.7-not reached) and the median PFS was 4.0 months (95% CI 3.6¿7.4). Treatment-related adverse events were reported in 71% of participants; 19% were grade 3 or 4. For participants who enrolled in Part 2, the OTRR was 10%; the median DOR was 13.5 months (95% CI 4.8¿19.7) and the median PFS 2.6 months (95% CI 2.2¿3.8). Treatment-related adverse events occurred in 80% of these participants; 49% had grade 3, 4 or 5. The median OS was 24 months (95% CI 16¿28) from time of enrolment in Part 1. Conclusions: Nivolumab monotherapy had a modest effect overall, with a few participants experiencing a long DOR. Sequential combination immunotherapy by addition of ipilimumab in the context of disease progression to nivolumab in nccRCC is not supported by this study, with only a minority of participants benefiting from this strategy.
|
||||||||||
2024 |
Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al., 'Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.', Lancet Oncol, 25 99-107 (2024) [C1]
|
Nova | |||||||||
2023 |
Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, et al., 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).', Ther Adv Med Oncol, 15 17588359231156392 (2023) [C1]
|
||||||||||
2023 |
Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, et al., 'Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.', Lancet Oncol, 24 881-891 (2023) [C1]
|
||||||||||
2023 |
Dowdell A, Marsland M, Faulkner S, Gedye C, Lynam J, Griffin CP, et al., 'Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy', FASEB BIOADVANCES, 5 211-220 (2023) [C1]
|
Nova | |||||||||
2023 |
Marsland M, Dowdell A, Faulkner S, Gedye C, Lynam J, Griffin CP, et al., 'The Membrane Protein Sortilin Is a Potential Biomarker and Target for Glioblastoma', Cancers, 15 2514-2514 [C1]
|
Nova | |||||||||
2023 |
Sim H-W, Wachsmuth L, Barnes EH, Yip S, Koh E-S, Hall M, et al., 'NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.', Neurooncol Adv, 5 vdad124 (2023) [C1]
|
||||||||||
2023 |
Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, et al., 'Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.', Neuro Oncol, 25 339-350 (2023) [C1]
|
||||||||||
2023 |
Marsland M, Dowdell A, Faulkner S, Jobling P, Rush RA, Gedye C, et al., 'ProNGF Expression and Targeting in Glioblastoma Multiforme.', Int J Mol Sci, 24 (2023) [C1]
|
Nova | |||||||||
2022 |
Gedye C, Navani V, 'Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes', Biochimica et Biophysica Acta - Reviews on Cancer, 1877 (2022) [C1] Cytotoxic chemotherapy and targeted therapies help people with advanced cancers, but for most, treatment fails. Cancer heterogeneity is one cause of treatment failure, but also su... [more] Cytotoxic chemotherapy and targeted therapies help people with advanced cancers, but for most, treatment fails. Cancer heterogeneity is one cause of treatment failure, but also suggests an opportunity to improve outcomes; reconceptualising cancer therapy as an ecological problem offers the strategy of adaptive therapy. If an agent is active against a patient's cancer, instead of traditional continuous dosing at the maximum tolerated dose until treatment failure, the patient and their oncologist may instead choose to pause treatment as soon as the cancer responds. When tumour burden increases, the cancer is rechallenged with the same agent in hope of delivering another response, ideally before symptoms occur or quality-of-life is impacted. These ¿loops¿ of ¿pause/restart¿ allows an active treatment to be used strategically, to delay the development of evolutionary selection within the cancer, delaying the onset of treatment resistance, controlling the cancer for longer. Modelling predicts patients can navigate several ¿loops¿, potentially increasing the utility of an active treatment by multiples, and early trials suggest at least doubling of progression-free survival. In this narrative review we confront how cancer heterogeneity limits treatment effectiveness, re-examine cancer as an ecological problem, review the data supporting adaptive therapy and outline the challenges and opportunities faced in clinical practice to implement this evolutionary concept. In an era where multiple novel active anti-neoplastic agents are being used with ancient inflexibile maximum tolerated dose for maximum duration approaches, adaptive dosing offers a personalised, n = 1 approach to cancer therapy selection.
|
Nova | |||||||||
2022 |
Roubaud G, Oezgueroglu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, et al., 'Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study', EUROPEAN JOURNAL OF CANCER, 170 73-84 (2022) [C1]
|
||||||||||
2022 |
Matsuyama M, Sachchithananthan M, Leonard R, Besser M, Nowak AK, Truran D, et al., 'What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry', Neuro-Oncology Practice, 9 68-78 (2022) [C1] Background: The goal of a clinical quality registry is to deliver immediate gains in survival and quality of life by delivering timely feedback to practitioners, thereby ensuring ... [more] Background: The goal of a clinical quality registry is to deliver immediate gains in survival and quality of life by delivering timely feedback to practitioners, thereby ensuring every patient receives the best existing treatment. We are developing an Australian Brain Cancer Registry (ABCR) to identify, describe, and measure the impact of the variation and gaps in brain cancer care from the time of diagnosis to the end of life. Methods: To determine a set of clinical quality indicators (CQIs) for the ABCR, a database and internet search were used to identify relevant guidelines, which were then assessed for quality using the AGREE II Global Rating Scale. Potential indicators were extracted from 21 clinical guidelines, ranked using a modified Delphi process completed in 2 rounds by a panel of experts and other stakeholders, and refined by a multidisciplinary Working Group. Results: Nineteen key quality reporting domains were chosen, specified by 57 CQIs detailing the specific inclusion and outcome characteristics to be reported. Conclusion: The selected CQIs will form the basis for the ABCR, provide a framework for achievable data collection, and specify best practices for patients and health care providers, with a view to improving care for brain cancer patients. To our knowledge, the systematic and comprehensive approach we have taken is a world first in selecting the reporting specifications for a brain cancer clinical registry.
|
||||||||||
2022 |
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al., 'PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [ Background: Previously, results from the TheraP trial showed that treatment with lutetium-177 [177Lu]Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response rat... [more] Background: Previously, results from the TheraP trial showed that treatment with lutetium-177 [177Lu]Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response rate and progression-free survival compared with cabazitaxel in men with metastatic castration-resistant prostate cancer. In this study, we aimed to analyse gallium-68 [68Ga]Ga-PSMA-11 PET (PSMA-PET) and 2-[18F]fluoro-2-deoxy-D-glucose PET (FDG-PET) imaging parameters as predictive and prognostic biomarkers in this patient population. Methods: TheraP was a multicentre, open-label, randomised phase 2 trial that recruited men with metastatic castration-resistant prostate cancer after treatment with docetaxel who were suitable for cabazitaxel from 11 hospitals in Australia. Participants were required to be 18 years old or older; have adequate haematological, renal, and liver function; and an Eastern Cooperative Oncology Group performance status of 0¿2. Participants were randomly assigned (1:1) using a centralised system using minimisation with a random component and that stratified patients by disease burden, previous treatment with enzalutamide or abiraterone, and study site. Patients were either given cabazitaxel (20 mg/m2 intravenously every 3 weeks for up to ten cycles) or [177Lu]Lu-PSMA-617 (6·0¿8·5 GBq intravenously every 6 weeks for up to six cycles). The primary study endpoint, analysed previously, was PSA response rate. The prespecified tertiary study endpoint was association between total tumour quantitative parameters on PSMA-PET, FDG-PET, and baseline characteristics with clinical outcomes. A SUVmean of 10 or higher on PSMA-PET was evaluated as a predictive biomarker for response to [177Lu]Lu-PSMA-617 versus cabazitaxel. A metabolic tumour volume (MTV) of 200 mL or higher on FDG-PET was tested as a prognostic biomarker. Both cutoff points were prespecified. The analysis was intention-to-treat, using logistic regression. This trial is registered with ClinicalTrials.gov, NCT03392428. Findings: 200 patients were randomly assigned between Feb 6, 2018, and Sept 3, 2019. 101 men were assigned to the cabazitaxel group and 99 were assigned to the [177Lu]Lu-PSMA-617 group. The median follow-up at data cutoff of July 20, 2020, was 18·4 months (IQR 12·8¿21·8). 35 (35%) of 99 men who were assigned [177Lu]Lu-PSMA-617 and 30 (30%) of 101 men who were assigned cabazitaxel had high PSMA uptake (SUVmean of =10). Odds of PSA response to [177Lu]Lu-PSMA-617 versus cabazitaxel were significantly higher for men with SUVmean of 10 or higher compared with those with SUVmean of less than 10 (odds ratio [OR] 12·19 [95% CI 3·42¿58·76] vs 2·22 [1·11¿4·51]; padj=0·039 for treatment-by-SUVmean interaction). PSA response rate for [177Lu]Lu-PSMA-617 compared with cabazitaxel was 32 (91% [95% CI 76¿98]) of 35 men versus 14 (47% [29¿65]) of 30 men in patients with SUVmean of 10 or higher, and 33 (52% [39¿64]) of 64 men versus 23 (32% [22¿45]) of 71 men in those with SUVmean of less than 10. High-volume disease on FDG-PET (MTV =200 mL) was seen in 30 (30%) of 99 men who were assigned [177Lu]Lu-PSMA-617 and 30 (30%) of 101 men who were assigned cabazitaxel. PSA response rate for both treatment groups combined for FDG-PET MTV of 200 mL or higher versus FDG-PET MTV of less than 200 mL was 23 (38% [95% CI 26¿52]) of 60 men versus 79 (56% [48¿65]) of 140 men (OR 0·44, 95% CI 0·23¿0·84; padj=0·035). Interpretation: In men with metastatic castration-resistant prostate cancer, PSMA-PET SUVmean was predictive of higher likelihood of favourable response to [177Lu]Lu-PSMA-617 than cabazitaxel, which provides guidance for optimal [177Lu]Lu-PSMA-617 use. High FDG-PET MTV was associated with lower responses regardless of randomly assigned treatment, warranting further research for treatment intensification. A strength of this analysis is the validation of pre-specified cutpoints within a multicentre, randomised, controlled trial. Quantitative PET parameters used, however, require specialise...
|
||||||||||
2022 |
Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, et al., '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial.', J Nucl Med, 63 560-566 (2022) [C1]
|
||||||||||
2022 |
Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, et al., 'Tumor Genomic Testing for \4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).', Clin Cancer Res, 28 1518-1530 (2022) [C1]
|
||||||||||
2022 |
O Dea A, Gedye C, Jago B, Paterson C, 'Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review', Journal of Cancer Survivorship, 16 1279-1295 (2022) [C1] Purpose: To synthesize existing evidence on the unmet supportive care needs of people affected by kidney cancer, across the cancer care continuum. Methods: A systematic review was... [more] Purpose: To synthesize existing evidence on the unmet supportive care needs of people affected by kidney cancer, across the cancer care continuum. Methods: A systematic review was conducted according to the PRISMA Statement Guidelines. Electronic databases (CINAHL, MEDLINE, and PsychINFO) were searched using key search terms. Articles were assessed according to pre-specified eligibility criteria. Data extraction and quality appraisal were conducted. The findings were integrated in a narrative synthesis. Results: One thousand sixty-three publications were screened, and 18 publications met the inclusion criteria. The following domains of unmet needs in order of frequency included psychological/emotional needs (17/18: 94%), physical needs (10/18: 56%), social needs (4/18: 22%), interpersonal/intimacy needs (4/18: 22%), patient-clinician communication needs (3/18: 17%), family-related needs (3/18: 17%), health system/information needs (3/18: 17%), spiritual needs (3/18: 17%), daily living needs (2/18: 11%), practical needs (1/18: 6%), and cognitive needs (1/18: 6%). Conclusions: There was a wide range of unmet supportive care needs experienced by people diagnosed with kidney cancer. A prominent focus was on psychological and physical needs. Further research is needed to understand how clinical (stage/treatment) and demographic (age/socio-economic/ethnicity) variables may moderate or mediate the relationship with unmet needs over time. With many unmet needs identified, this review provides a starting place to inform future work to address the complex unmet supportive care needs of people affected by kidney cancer. Implications for Cancer Survivors: Individuals living with kidney cancer have many unmet supportive care needs, and future research is needed to learn about what are the most pressing needs and how to best address these concerns to ensure holistic person-centered care is delivered.
|
Nova | |||||||||
2021 |
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al., '[Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial', LANCET, 397 797-804 (2021) [C1]
|
Nova | |||||||||
2021 |
Khasraw M, Weller M, Lorente D, Kolibaba K, Lee CK, Gedye C, et al., 'Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-ß and PD-L1: Results from a phase i expansion cohort in patients with recurrent glioblastoma', Neuro-Oncology Advances, 3 (2021) [C1] Background. For patients with recurrent glioblastoma (rGBM), there are few options following treatment failure with radiotherapy plus temozolomide. Bintrafusp alfa is a first-in-c... [more] Background. For patients with recurrent glioblastoma (rGBM), there are few options following treatment failure with radiotherapy plus temozolomide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-ßRII receptor (a TGF-ß "trap") fused to a human IgG1 antibody blocking PD-L1. Methods. In this phase I, open-label expansion cohort (NCT02517398), patients with rGBM that progressed after radiotherapy plus temozolomide received bintrafusp alfa 1200 mg Q2W until disease progression, unacceptable toxicity, or trial withdrawal. Response was assessed per RANO criteria. The primary endpoint was disease control rate (DCR); secondary endpoints included safety. Results. As of August 24, 2018, 35 patients received bintrafusp alfa for a median of 1.8 (range, 0.5-20.7) months. Eight patients (22.9%) experienced disease control as assessed by an independent review committee: 2 had a partial response, 4 had stable disease, and 2 had non-complete response/non-progressive disease. Median progressionfree survival (PFS) was 1.4 (95% confidence interval [CI], 1.2-1.6) months; 6- and 12-month PFS rates were 15.1% and 11.3%, respectively. Median overall survival (OS) was 5.3 (95% CI, 2.6-9.4) months; 6- and 12-month OS rates were 44.5% and 30.8%, respectively. The DCR (95% CI) was 66.7% (22.3-95.7%) for patients with IDH-mutant GBM (n = 6) and 13.8% (3.9-31.7%) for patients with IDH-wild-type GBM (n = 29). Disease control was seen regardless of PD-L1 expression. Twenty-five patients (71.4%) experienced treatment-related adverse events (grade =3; 17.1% [n = 6]). Conclusions. The percentage of patients achieving disease control and the manageable safety profile may warrant further investigation of bintrafusp alfa in GBM.
|
||||||||||
2021 |
Birgersson M, Chi M, Miller C, Brzozowski JS, Brown J, Schofield L, et al., 'A Novel Role for Brain and Acute Leukemia Cytoplasmic (BAALC) in Human Breast Cancer Metastasis', FRONTIERS IN ONCOLOGY, 11 (2021) [C1]
|
Nova | |||||||||
2021 |
Merseburger AS, Castellano D, Powles T, Loriot Y, Retz M, Voortman J, et al., 'Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice', JOURNAL OF UROLOGY, 206 241-250 (2021) [C1]
|
||||||||||
2021 |
Travers A, Adler K, Blanchard G, Bonaventura T, Charlton J, Day F, et al., 'Business as unusual: medical oncology services adapt and deliver during COVID-19', Internal Medicine Journal, 51 673-681 (2021) [C1] Background: The COVID-19 pandemic has challenged cancer care globally, introducing resource limitations and competing risks into clinical practice. Aims: To describe the COVID-19 ... [more] Background: The COVID-19 pandemic has challenged cancer care globally, introducing resource limitations and competing risks into clinical practice. Aims: To describe the COVID-19 impact on medical oncology care provision in an Australian setting. Methods: Calvary Mater Newcastle and Newcastle Private Hospital medical oncology data from 1 February to 31 April 2019 versus 2020 were retrospectively analysed. Results: Three hundred and sixty-four inpatient admissions occurred in 2020, 21% less than in 2019. Total inpatient days decreased by 22% (2842 vs 2203). April was most impacted (36% and 44% fewer admissions and inpatient days respectively). Mean length of stay remained unchanged (6.4 vs 6.2 days, P = 0.7). In all, 5072 outpatient consultations were conducted, including 417 new-patient consultations (4% and 6% increase on 2019 respectively). Telephone consultations (0 vs 1380) replaced one-quarter of face-to-face consultations (4859 vs 3623, -25%), with minimal telehealth use (6 vs 69). Day Treatment Centre encounters remained stable (3751 vs 3444, -8%). The proportion of new patients planned for palliative treatment decreased (35% vs 28%, P = 0.04), observation increased (16% vs 23%, P¿=¿0.04) and curative intent treatment was unchanged (both 41%). Recruiting clinical trials decreased by one-third (45 vs 30), two trials were activated (vs 5 in 2019) and 45% fewer patients consented to trial participation (62 vs 34). Conclusion: Our medical oncology teams adapted rapidly to COVID-19 with significant changes to care provision, including fewer hospital admissions, a notable transition to telephone-based outpatient clinics and reduced clinical trial activity. The continuum of care was largely defended despite pandemic considerations and growing service volumes.
|
Nova | |||||||||
2020 |
Davis JS, Ferreira D, Paige E, Gedye C, Boyle M, 'Infectious complications of biological and small molecule targeted immunomodulatory therapies', Clinical Microbiology Reviews, 33 1-117 (2020) [C1] The past 2 decades have seen a revolution in our approach to therapeutic immunosuppression. We have moved from relying on broadly active traditional medications, such as prednisol... [more] The past 2 decades have seen a revolution in our approach to therapeutic immunosuppression. We have moved from relying on broadly active traditional medications, such as prednisolone or methotrexate, toward more specific agents that often target a single receptor, cytokine, or cell type, using monoclonal antibodies, fusion proteins, or targeted small molecules. This change has transformed the treatment of many conditions, including rheumatoid arthritis, cancers, asthma, and inflammatory bowel disease, but along with the benefits have come risks. Contrary to the hope that these more specific agents would have minimal and predictable infectious sequelae, infectious complications have emerged as a major stumbling block for many of these agents. Furthermore, the growing number and complexity of available biologic agents makes it difficult for clinicians to maintain current knowledge, and most review articles focus on a particular target disease or class of agent. In this article, we review the current state of knowledge about infectious complications of biologic and small molecule immunomodulatory agents, aiming to create a single resource relevant to a broad range of clinicians and researchers. For each of 19 classes of agent, we discuss the mechanism of action, the risk and types of infectious complications, and recommendations for prevention of infection.
|
Nova | |||||||||
2020 |
Afrin F, Chi M, Eamens AL, Duchatel RJ, Douglas AM, Schneider J, et al., 'Can hemp help? Low-THC cannabis and non-THC cannabinoids for the treatment of cancer', Cancers, 12 (2020) [C1]
|
Nova | |||||||||
2020 |
Yoon J-Y, Gedye C, Paterson J, Ailles L, 'Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored', BMC CANCER, 20 (2020) [C1]
|
Nova | |||||||||
2020 |
Gedye C, Sachchithananthan M, Leonard R, Jeffree RL, Buckland ME, Ziegler DS, et al., 'Driving innovation through collaboration: Development of clinical annotation datasets for brain cancer biobanking', Econometrics Journal, 23 31-37 (2020) [C1] © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. A ... [more] © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. A key component of cancer research is the availability of clinical samples with appropriately annotated clinical data. Biobanks facilitate research by collecting/storing various types of clinical samples for research. Brain Cancer Biobanking Australia (BCBA) was established to facilitate the networking of brain cancer biobanking operations Australia-wide. Maximizing biospecimen utility in a networked biobanking environment requires the standardization of procedures and data across different sites. The aim of this research was to scope and develop a recommended clinical annotation dataset both for pediatric and adult brain cancer biobanks. Methods: A multidisciplinary working group consisting of members from the BCBA Consortium was established to develop clinical dataset recommendations for brain cancer biobanks. A literature search was undertaken to identify any published clinical dataset recommendations for brain cancer biobanks. An audit of data items collected and stored by BCBA member biobanks was also conducted to survey current clinical data collection practices across the BCBA network. Results: BCBA has developed a clinical annotation dataset recommendation for pediatric and adult brain cancer biobanks. The clinical dataset recommendation has 5 clinical data categories: demographic, clinical and radiological diagnosis and surgery, neuropathological diagnosis, patient treatment, and patient follow-up. The data fields have been categorized into 1 of 3 tiers; essential, preferred, and comprehensive. This enables biobanks and researchers to prioritize appropriately where resources are limited. Conclusion: This dataset can be used to guide the integration of data from multiple existing biobanks for research studies and for planning prospective brain cancer biobanking activities.
|
Nova | |||||||||
2019 |
Fradgley EA, Chong SE, Cox ME, Gedye C, Paul CL, 'Patients experiences and preferences for opt-in models and health professional involvement in biobanking consent: A cross-sectional survey of Australian cancer outpatients', Asia-Pacific Journal of Clinical Oncology, 15 31-37 (2019) [C1] Background: Many biobanks rely upon patients¿ willingness to donate biospecimens and healthcare professionals to initiate opt-in consent processes. This study explored if: (1) pat... [more] Background: Many biobanks rely upon patients¿ willingness to donate biospecimens and healthcare professionals to initiate opt-in consent processes. This study explored if: (1) patients accept opt-in or opt-out consent models with varying levels of professional involvement; (2) professionals discuss participation with specific patient groups; and (3) this discussion is associated with patient knowledge of biobanking processes. Methods: Outpatients completed surveys at a tertiary cancer center in New South Wales, Australia. Eligible participants were English-speaking adults who recently had cancer-related surgery. Participants completed 27 questions exploring acceptable consent models, biobanking experiences, knowledge, and willingness. Logistic regression and chi-square tests examined differences in the characteristics and knowledge of participants who were offered the opportunity to participate versus those who were not. Results: A total of 113 outpatients participated (97% response). Most participants (92%) found opt-out, patient-initiated consent acceptable; however, high acceptability was reported for all models except for opt-in, patient-initiated consent (58%). University or technical qualifications (P = 0.001) was associated with increased odds (OR¿=¿4.5) of being offered biobanking. The majority did not know what occurred to samples after surgery (59.3%) or pathology review (81.4%) and ability to answer these questions was associated with discussion of participation (P¿<¿0.001). Of the few outpatients who discussed biobanking with their doctor (29%), all consented. Conclusion: Professional-initiated, opt-in consent resulted in a few educated patients being approached; greater professional initiation of consent would be fruitful as most patients were willing to participate if asked. However, other consent approaches minimizing professional involvement were as acceptable to participants warranting further consideration.
|
Nova | |||||||||
2019 |
Rowe CW, Faulkner S, Paul JW, Tolosa JM, Gedye C, Bendinelli C, et al., 'The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis.', BMC endocrine disorders, 19 128 (2019) [C1]
|
Nova | |||||||||
2019 |
Rowe CW, Dill T, Faulkner S, Gedye C, Paul JW, Tolosa JM, et al., 'The precursor for nerve growth factor (ProNGF) in thyroid cancer lymph node metastases: Correlation with primary tumour and pathological variables', International Journal of Molecular Sciences, 20 1-13 (2019) [C1]
|
Nova | |||||||||
2019 |
Peters S, Clézardin P, Márquez-Rodas I, Niepel D, Gedye C, 'The RANK RANKL axis: an opportunity for drug repurposing in cancer?', Clinical and Translational Oncology, 21 977-991 (2019) [C1]
|
Nova | |||||||||
2018 | Gedye C, 'The diverse landscape of genitourinary cancer immunotherapy', Cancer Forum, 42 29-39 (2018) [C1] | Nova | |||||||||
2018 |
Almazi JG, Pockney P, Gedye C, Smith ND, Hondermarck H, Verrills NM, Dun MD, 'Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer.', Proteomics. Clinical applications, 12 e1700121 (2018) [C1]
|
Nova | |||||||||
2018 |
Fradgley EA, Chong SE, Cox ME, Paul CL, Gedye C, 'Enlisting the willing: A study of healthcare professional initiated and opt-in biobanking consent reveals improvement opportunities throughout the registration process', European Journal of Cancer, 89 36-41 (2018) [C1] Biobanking consent processes should accord with patients' preferences and be offered in a consistent and systematic manner. However, these aims can be difficult to achieve un... [more] Biobanking consent processes should accord with patients' preferences and be offered in a consistent and systematic manner. However, these aims can be difficult to achieve under healthcare professionals' (HCPs) time-constrained workflows, resulting in low participation rates. This current perspective provides a brief overview of HCP involvement in consent and reports new data on participant attrition at each step of the biobanking consent process as experienced by 113 patients at an Australian tertiary cancer centre. To determine attrition in this HCP-driven consent process, we reviewed medical records for the following events: inclusion of biobanking consent forms; visible patient and HCP signatures; consent status selected (decline or accept) and specimen registration with local biobank. Accessible medical records revealed the following data: 75 of 85 records included viewable forms; 22 of 85 records included patient and 19 of 85 included HCP signatures; 15 of 85 records included signed and completed forms and 3 of 85 had samples banked with annotated clinical data. We compared these data with self-reported experiences of being approached to participate by HCPs. Of the 15 participants (17.6%) who successfully completed consent, only five could recall being asked and providing consent. The low enrolment rate is a considerable lost opportunity because most patients (59%) who were not asked to participate indicated they would have consented if asked. Furthermore, in comparing self-reported experiences with medical records, we believe cancer patients' preferences for participation are mismatched with actual biobanking enrolment, which has considerable attrition at each step in the consent process.
|
Nova | |||||||||
2017 |
Rowe CW, Paul JW, Gedye C, Tolosa JM, Bendinelli C, McGrath S, Smith R, 'Targeting the TSH receptor in thyroid cancer', Endocrine-Related Cancer, 24 R191-R202 (2017) [C1] Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone re... [more] Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSHR has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.
|
Nova | |||||||||
2017 |
Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, et al., 'An Immune Atlas of Clear Cell Renal Cell Carcinoma', Cell, 169 736-749.e18 (2017) [C1] Immune cells in the tumor microenvironment modulate cancer progression and are attractive therapeutic targets. Macrophages and T¿cells are key components of the microenvironment, ... [more] Immune cells in the tumor microenvironment modulate cancer progression and are attractive therapeutic targets. Macrophages and T¿cells are key components of the microenvironment, yet their phenotypes and relationships in this ecosystem and to clinical outcomes are ill defined. We used mass cytometry with extensive antibody panels to perform in-depth immune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and five healthy controls. In 3.5 million measured cells, we identified 17 tumor-associated macrophage phenotypes, 22 T¿cell phenotypes, and a distinct immune composition correlated with progression-free survival, thereby presenting an in-depth human atlas of the immune tumor microenvironment in this disease. This study revealed potential biomarkers and targets for immunotherapy development and validated tools that can be used for immune profiling of other tumor types.
|
Nova | |||||||||
2016 |
Khoja L, Atenafu EG, Ye Q, Gedye C, Chappell M, Hogg D, et al., 'Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma', Oncology Letters, 11 1581-1585 (2016) [C1] Approved by the Food and Drug Administration in 2011, the anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitor ipilimumab has delivered a survival benefit of =3 y... [more] Approved by the Food and Drug Administration in 2011, the anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitor ipilimumab has delivered a survival benefit of =3 years in a subset of metastatic melanoma patients. After participating in the registration trial, patients were treated with this agent in routine practice. Toxicity and efficacy of agents in ¿real world¿ settings may differ from trials. The present study aimed to evaluate, with respect to toxicity and outcome, all patients treated with ipilimumab to date at the Princess Margaret Hospital (Toronto, Canada). Patients treated with ipilimumab between 2008 and 2013 were identified, and patient characteristics (age, gender, tumour burden, oncogenic mutation status, number of treatments received and toxicities from treatment) were collected. Progression-free survival (PFS) and overall survival (OS) were calculated from the commencement of ipilimumab treatment. Associations between clinical characteristics and outcome or toxicity were assessed. Between 2008 and 2013, 129 patients with metastatic cutaneous melanoma were treated. Since, during this period, ipilimumab was approved in the second line setting, ipilimumab was delivered in the second or subsequent line in all patients, and 70% did not receive any further anticancer therapy. Immune-related toxicities were observed, the onset of which varied from 1 to 162 days. The majority resolved within 6 weeks of the final treatment, with the exception of endocrinopathies and bowel related toxicity. The median PFS and OS were 2.83 and 8.44 months, respectively. No pre-treatment factor independently predicted toxicity. The number of infusions (4 vs. =3) and presence of toxicity were significantly associated with superior survival. The onset of toxicity secondary to ipilimumab could occur later than previously reported. Toxicities were manageable, but required long-term vigilance.
|
Nova | |||||||||
2016 |
Gedye C, Sirskyj D, Lobo NC, Meens J, Hyatt E, Robinette M, et al., 'Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma', Scientific Reports, 6 (2016) [C1] Rare cancer stem cells (CSC) are proposed to be responsible for tumour propagation and re-initiation and are functionally defined by identifying tumour-initiating cells (TICs) usi... [more] Rare cancer stem cells (CSC) are proposed to be responsible for tumour propagation and re-initiation and are functionally defined by identifying tumour-initiating cells (TICs) using the xenotransplantation limiting dilution assay (LDA). While TICs in clear cell renal cell carcinoma (ccRCC) appeared rare in NOD/SCID/IL2R¿ 3 -/- (NSG) mice, xenografts formed more efficiently from small tumour fragments, indicating the LDA underestimated ccRCC TIC frequency. Mechanistic interrogation of the LDA identified multiple steps that influence ccRCC TIC quantitation. For example, tissue disaggregation destroys most ccRCC cells, common assays significantly overestimate tumour cell viability, and microenvironmental supplementation with human extracellular factors or pharmacological inhibition of anoikis increase clonogenicity and tumourigenicity of ccRCC cell lines and primary tumour cells. Identification of these previously uncharacterized concerns that cumulatively lead to substantial underestimation of TICs in ccRCC provides a framework for development of more accurate TIC assays in the future, both for this disease and for other cancers.
|
Nova | |||||||||
2016 |
Gedye C, Fleming J, 'Forsaking cures for cancer: why are we discarding the tumour biospecimens of most patients?', MEDICAL JOURNAL OF AUSTRALIA, 204 297-298 (2016) [C1]
|
Nova | |||||||||
2016 |
Chia PL, Gedye C, Boutros PC, Wheatley-Price P, John T, 'Current and Evolving Methods to Visualize Biological Data in Cancer Research', JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 108 (2016) [C1]
|
Nova | |||||||||
2016 |
Lobo NC, Gedye C, Apostoli AJ, Brown KR, Paterson J, Stickle N, et al., 'Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: Clinically relevant models for research and personalized medicine', BMC Cancer, 16 (2016) [C1]
|
Nova | |||||||||
2016 |
Gedye C, Cardwell T, Dimopoulos N, Tan BS, Jackson H, Svobodová S, et al., 'Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro', Stem Cell Reviews and Reports, 12 156-161 (2016) [C1] Cancer cell lines can be useful to model cancer stem cells. Infection with Mycoplasma species is an insidious problem in mammalian cell culture. While investigating stem-like prop... [more] Cancer cell lines can be useful to model cancer stem cells. Infection with Mycoplasma species is an insidious problem in mammalian cell culture. While investigating stem-like properties in early passage melanoma cell lines, we noted poorly reproducible results from an aliquot of a cell line that was later found to be infected with Mycoplasma hyorhinis. Deliberate infection of other early passage melanoma cell lines aliquots induced variable and unpredictable effects on expression of putative cancer stem cell markers, clonogenicity, proliferation and global gene expression. Cell lines established in stem cell media (SCM) were equally susceptible. Mycoplasma status is rarely reported in publications using cultured cells to study the cancer stem cell hypothesis. Our work highlights the importance of surveillance for Mycoplasma infection while using any cultured cells to interrogate tumor heterogeneity.
|
Nova | |||||||||
2016 |
Khoja L, Kibiro M, Metser U, Gedye C, Hogg D, Butler MO, et al., 'Patterns of response to anti-PD-1 treatment: An exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients', British Journal of Cancer, 115 1186-1192 (2016) [C1] Background:Radiological assessment of response to checkpoint inhibitors remains imperfect. We evaluated individual lesion and inter-patient response by response evaluation (RECIST... [more] Background:Radiological assessment of response to checkpoint inhibitors remains imperfect. We evaluated individual lesion and inter-patient response by response evaluation (RECIST) 1.1, immune-related response criteria (irRC), CHOI and modified CHOI (mCHOI) and correlated response with overall survival (OS).Methods:Thirty-seven patients with 567 measurable lesions treated with pembrolizumab in the Keynote 001 trial were studied. Association of response with OS was determined.Results:Response varied according to site; lung lesions had the highest rate of complete response (69 out of 163 (42%) vs other sites 71 out of 404 (18%), P<0.0001). Delayed response post first scan was seen in 2 out of 37 (5%) deemed progressive (PD) by RECIST and 2 out of 14 (14%) deemed PD by irRC. Modified CHOI criteria showed response of 38% (14 out of 37). Change in tumour size and density on first follow-up assessment was associated with OS with each 1000 mm 2 increase in tumour size from baseline increasing the hazard of dying by 25.9% (HR=1.259, (95% CI=1.116-1.420), P=0.0002). Similarly, each 20HU increase in density increased the HR by 15% (HR=1.15, (95% CI 1.045-1.260), P=0.004). Response defined by any criteria had superior OS (CHOI P=0.0084; mCHOI P=0.0183; irRC P<0.0001 and RECIST P=0.0003).Conclusions:Response by any criterion was prognostic. Novel patterns of response and changes on treatment in tumour density suggest complex anti-tumour responses to immunotherapy.
|
Nova | |||||||||
2015 |
Gedye C, Boyle FM, 'Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annually', The Medical journal of Australia, 202 130 (2015) [C3]
|
||||||||||
2015 |
Gedye C, Boyle FM, 'Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annually', MEDICAL JOURNAL OF AUSTRALIA, 202 I-I (2015)
|
||||||||||
2015 |
Gedye C, van der Westhuizen A, John T, 'Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities.', Intern Med J, 45 696-701 (2015) [C1]
|
Nova | |||||||||
2014 |
Gedye CA, Hussain A, Paterson J, Smrke A, Saini H, Meyer M, 'Correction: Cell surface profiling using high-throughput flow cytometry: A platform for biomarker discovery and analysis of cellular heterogeneity', PLoS ONE, 9 (2014)
|
||||||||||
2014 |
Naert K, Al Habeeb A, Gedye C, Ghazarian D, 'Targeted therapy in melanoma: The era of personalized medicine', Diagnostic Histopathology, (2014) [C1] Malignant melanoma is the most aggressive of all cutaneous tumours, with over 76, 000 new cases and 9700 deaths estimated for 2014 in the United States.1 In Canada, both the incid... [more] Malignant melanoma is the most aggressive of all cutaneous tumours, with over 76, 000 new cases and 9700 deaths estimated for 2014 in the United States.1 In Canada, both the incidence and mortality of melanoma are increasing, with a risk of developing melanoma being 1 in 59 for men and 1 in 73 for women.2 The incidence of melanoma is higher in Australia, with a risk of 1 in 14 for males and 1 in 23 for females to age 85 reported for 2009.3 Although early melanoma can be managed surgically, until recently there have been few advances in the treatment of advanced melanoma. However, with the introduction of molecular targeted therapies, the landscape of melanoma treatment has changed dramatically in the past five years, resulting in improved survival rates for patients with metastatic disease. In this review, we will discuss the molecular basis and implementation for some of these novel treatments with particular emphasis on BRAF and BRAF inhibitors.
|
Nova | |||||||||
2013 |
Sompallae R, Hofmann O, Maher CA, Gedye C, Behren A, Vitezic M, et al., 'A comprehensive promoter landscape identifies a novel promoter for CD PROM1 is the gene encoding prominin-1 or CD133, an important cell surface marker for the isolation of both normal and cancer stem cells. PROM1 transcripts initiate at a range of t... [more] PROM1 is the gene encoding prominin-1 or CD133, an important cell surface marker for the isolation of both normal and cancer stem cells. PROM1 transcripts initiate at a range of transcription start sites (TSS) associated with distinct tissue and cancer expression profiles. Using high resolution Cap Analysis of Gene Expression (CAGE) sequencing we characterize TSS utilization across a broad range of normal and developmental tissues. We identify a novel proximal promoter (P6) within CD133+ melanoma cell lines and stem cells. Additional exon array sampling finds P6 to be active in populations enriched for mesenchyme, neural stem cells and within CD133+ enriched Ewing sarcomas. The P6 promoter is enriched with respect to previously characterized PROM1 promoters for a HMGI/Y (HMGA1) family transcription factor binding site motif and exhibits different epigenetic modifications relative to the canonical promoter region of PROM1.© 2013 Sompallae, Hofmann, Maher, Gedye, Behren, Vitezic, Daub, Devalle, Caballero, Carninci, Hayashizaki, Lawlor, Cebon and Hide.
|
||||||||||
Show 84 more journal articles |
Conference (73 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2023 |
Gedye C, McFarlane J, Zardawi S, Kugashiya S, Jalewa J, Kim S, et al., 'Feasibility, acceptability and safety of personalized adaptive enzalutamide therapy in people with metastatic castrate-resistant prostate cancer (mCRPC): EnzAdapt', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2023)
|
||||
2023 | Lee C-H, Gurney H, Atduev V, Suarez C, Duran MAC, Pook DW, et al., 'First-line lenvatinib plus pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.', JOURNAL OF CLINICAL ONCOLOGY, IL, Chicago (2023) | ||||
2023 | Sternberg CN, Loriot Y, Choy E, Castellano D, Moreno FL-R, Banna GL, et al., 'Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC).', JOURNAL OF CLINICAL ONCOLOGY, IL, Chicago (2023) | ||||
2020 | Grimison PS, Stockler MR, Kirby A, Walsh A, Lintzeris N, Cheung Y, et al., 'Results of crossover phase 2 component of randomised placebo-controlled trial evaluating oral THC/CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV)', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020) | ||||
2015 |
Laegdsgaard P, Nielsen S, Koegelenberg A, Goode S, Thorne R, Lund D, et al., 'A NEW VENTURE FOR THE HUNTER CANCER BIOBANK-ESTABLISHMENT OF SEQUENTIAL BLOOD COLLECTION FOR BRAIN CANCER RESEARCH', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
||||
2014 |
Gedye C, Kurban G, Gallie BL, Leveridge MJ, Musquera M, Morales C, et al., 'Surgical ischemia and detection of clear cell renal cell carcinoma biomarkers', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2014)
|
||||
2014 |
Gedye C, Sirskyj D, Lobo NC, Hyatt E, Evans A, Finelli A, et al., 'Essential experimental steps and estimates of renal carcinoma initiating cells', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2014)
|
||||
2014 |
Gedye C, Sirskyj D, Hyatt E, Lobo N, Lourenco C, Evans A, et al., 'MESENCHYMAL DIFFERENTIATION PROGRAMS GOVERN VHL-MUTANT CLEAR CELL RENAL CANCER BIOLOGY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
||||
2014 |
Koegelenberg AM, Dean S, Nielsen S, Carroll R, Mellon A, Surgeons G, et al., 'THE IMPACT OF INTEGRATING SYSTEM CHANGES INTO ROUTINE HEALTHCARE PRACTICES VIA MODIFICATION OF EXISTING PROCESSES; A LOOK AT BIOBANKING CONSENT IN THE HUNTER REGION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
||||
2013 |
Gedye C, Sirskyj D, Lobo NC, Evans A, Fleshner NE, Robinette M, et al., 'VHL-mutant renal cell carcinomas contain cancer cells with mesenchymal phenotypes', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2013) [E3]
|
Nova | |||
2013 | Davidson A, Quirk J, Gedye C, Browning J, Bolton D, Davis I, 'Differential cancer/testis antigen expression in colony forming bladder cancer cell populations', BJU INTERNATIONAL, Melbourne, AUSTRALIA (2013) [E3] | Nova | |||
Show 70 more conferences |
Grants and Funding
Summary
Number of grants | 26 |
---|---|
Total funding | $15,123,512 |
Click on a grant title below to expand the full details for that specific grant.
20222 grants / $1,120,587
Cardiovascular disease and cancer: identifying shared disease pathways and pharmacological management$1,029,267
Funding body: Department of Health and Aged Care
Funding body | Department of Health and Aged Care |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo, Professor Murray Cairns, Doctor Heather Lee, Associate Professor Nikki Verrills, Doctor Craig Gedye, Doctor Tatt Jhong Haw, Professor John Attia, Professor Michael Kelso, Dr Daniel Tillett, Dr James Lynam, Dr James Lynam, Associate Professor Anoop Enjeti, Dr Susan Dent, Kerry Doyle, OAM, Susan Dent, Kerry Doyle, Anoop Enjeti, Michael Kelso, Daniel Tillett |
Scheme | MRFF - Cardiovascular Health Mission - Cardiovascular Health |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2025 |
GNo | G2200136 |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | Y |
An Effective Targeted Therapy For Glioblastoma $91,320
Funding body: Mark Hughes Foundation
Funding body | Mark Hughes Foundation |
---|---|
Project Team | Professor Hubert Hondermarck, Miss Amiee Dowdell, Doctor Sam Faulkner, Doctor Craig Gedye, Doctor Chen Chen Jiang, Associate Professor Phil Jobling, Doctor James Lynam, Mr Mark Marsland, Professor Robert Rush |
Scheme | Research Funding |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2200879 |
Type Of Funding | Scheme excluded from IGS |
Category | EXCL |
UON | Y |
20194 grants / $2,743,793
MAGMA Multi-Arm GlioblastoMa Australasia$2,421,993
Brain cancer is a challenging health problem to face. Brain cancers like glioblastoma and astrocytoma are (perhaps mercifully) relatively uncommon, so people suffering brain cancer are often treated in many different hospitals. It can be hard to coordinate studies and clinical trials between different hospitals and doctors, and so it can be more difficult to study and test ideas to improve treatments. We are extremely excited to be developing a new clinical trial for people with brain cancer, to be run by the Cooperative Trials Group
for Neuro-Oncology (COGNO) trying to reach out to as many patients and their doctors as possible across Australia (and hopefully in the future New Zealand too).
The clinical trial is called MAGMA (standing for Multi-Arm GlioblastoMa Australasia). The clinical trial aims to make small changes in the way that we use our existing treatments for brain cancer; small changes that we hope will have big impacts for future patients. Some clinical trials test new drugs or new treatments; these sometimes deliver a benefit but as often as not they can’t beat the standard treatment. MAGMA fills the gap in the other direction; when we have a treatment that we know does help, we seek to make it work better, aiming to keep people feeling well for longer.
The first two ideas (in the first two arms of the study) that we are testing in MAGMA are based around the chemotherapy drug commonly used in brain cancer, temozolomide. The standard treatment uses this chemotherapy drug daily with radiation treatment and then monthly for six months after radiation finishes.
Our two questions are 1) what if we started the chemotherapy as soon as possible after surgery, before the radiation starts? And 2) what if we carried on the monthly chemotherapy for as long as it seemed to be working – or can we take a break and start it again later if/when needed?
These kinds of simple questions have led to significant improvements in other cancers, and have changed how we recommend treatment to people with prostate cancer, ovarian cancer and other cancers.
We are incredibly grateful for the support of the Mark Hughes Foundation who are supporting the Australian Brain Cancer Mission that has provided the funding to support MAGMA through the Medical Research Future Fund.
Funding body: Cancer Australia
Funding body | Cancer Australia |
---|---|
Project Team | Gedye C, Nowak A, Hovey E, Koh E-S, Harrup R, Parkinson J, Barnes E, Jeffree R |
Scheme | Rare Disease and Rare Cancers |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2024 |
GNo | |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | N |
New horizons. Therapeutic applications for medicinal cannabis in the treatment of brain cancer.$190,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Dr Kelly McKelvey, Doctor Adjanie Patabendige, Doctor Ameha Woldu, Doctor Mengna Chi, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2020 |
GNo | G1900131 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
COgnitive impairment in People with glioma and distress in their INformal care-Givers: feasibility and acceptability of a systematic screening process and structured referral process$100,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Liz Fradgley, Professor Christine Paul, Conjoint Professor Peter Schofield, Doctor Craig Gedye, Conjoint Professor Stephen Ackland, Associate Professor Helen Wheeler, Ms Marina Kastelan, Sandy Nixon, Mrs Alisha Gooley, Associate Professor Fiona Schulte |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2021 |
GNo | G1801423 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Heterogeneity in Cancer$31,800
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Craig Gedye |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1900542 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20186 grants / $2,062,198
UNICAB: A phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1802)$1,173,201
Cabozantinib is an anti-cancer drug that works by blocking cancer cell growth. Cabozantinib has previously been used in the treatment of many cancers, including clear cell kidney cancer and thyroid cancer. However, it has not been tested in people with non-clear cell kidney cancer.
About 48 participants with non-clear cell kidney cancer are expected to participate in this study, from Australia.
Funding body: Ipsen Pty Ltd
Funding body | Ipsen Pty Ltd |
---|---|
Project Team | Pook D, Gedye C, Harris C, Davis I, Krieger L, McJannett M. |
Scheme | Research Project |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2023 |
GNo | |
Type Of Funding | C3211 - International For profit |
Category | 3211 |
UON | N |
Stereotactic Ablative Radiotherapy (SABR) as a New Precision Treatment Option in Kidney Cancer (ASSOCIATE INVESTIGATOR)$589,000
Associate Investigator
Funding body: Cancer Australia
Funding body | Cancer Australia |
---|---|
Project Team | Siva S, Kron T, Martin J, Christie D, Lawrentschuk N, De Abreu Lourenco R, Carmichael A, Vanneste B, Gedye C, Mathias B, Hofman M, Brook N, Lo S. |
Scheme | Priority-driven Collaborative Cancer Research Scheme |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | N |
A new biomarker to predict response to PARP inhibitors in glioblastoma$100,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1801446 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Investigating a new class of drugs for the treatment of brain cancer$99,997
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1701638 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
The Virtual Biobank$50,000
Funding body: Woodend Foundation
Funding body | Woodend Foundation |
---|---|
Project Team | Doctor Craig Gedye, Professor Marjorie Walker, Doctor Simon King, Doctor Bill Pascoe, Ms Cassandra Griffin, Dr Jamie Flynn, Dr JAMIE Flynn, Antony Martin, William Palmer |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2019 |
GNo | G1701611 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
EnzAdapt: feasibility, acceptability and safety of adaptive dosing of enzalutamide in men with metastatic castrate-resistant prostate cancer$50,000
When prostate cancer spreads, injections that suppress the male hormone testosterone can control the cancer for some time, but it almost always starts to grow again later. Hormone tablets to block testosterone on top of the injections can regain control of the cancer, but again, only for a limited time of about one year. Cancers grow like weeds; some of the cancer cells can be controlled by weedspray but other parts of the cancer aren’t affected and can flourish. These vulnerable and resistant cells of the cancer are often holding each other in balance; and when a treatment is used it can favour one group of cancer cells over another. This trial is designed to test the idea of taking breaks off taking hormone tablets, using them for long enough to control the cancer, but then stopping and saving them up until later to treat the cancer again (and again… and hopefully again and again). While every man’s cancer is predicted to eventually become resistant to hormone treatments, using hormone tablets in a sparing and cunning way is hoped to spread the benefit over a longer period of time, without more side-effects. Very early reports with other drugs support this idea; this will be the first trial testing this idea with enzalutamide (Xtandi). If this idea proves to be sound, it may improve the lives and survival of men with prostate cancer.
Funding body: Below the Belt Research Fund
Funding body | Below the Belt Research Fund |
---|---|
Project Team | Drs Mandaliya, Lynam, Mallesara, Bonaventura, Abell, Livshin, CelliMarchett |
Scheme | ANZUP Below the Belt Research Fund |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | C3112 - Aust Not for profit |
Category | 3112 |
UON | N |
20173 grants / $5,704,145
KeyPAD$2,413,500
The commonest kind of advanced kidney cancer is called clear cell kidney cancer. Immune therapies have been shown to be effective in about a quarter of patients with advanced clear cell kidney cancer after the standard tablet treatment has failed. This study will test if a drug (denosumab) usually used to treat osteoporosis (thinning of the bones) or cancer that has spread to the bones, can be added to the immune therapy to increase the ability of the body’s immune system to attack kidney cancer cells. This study is designed to assess the effects and safety of the combination of two drugs; pembrolizumab and denosumab. All participants on the trial will receive both treatments. Blood and cancer samples will be collected from each patient to better understand who has benefited and who has been failed by the treatment combination.
Funding body: MSD Australia and Amgen Australia
Funding body | MSD Australia and Amgen Australia |
---|---|
Project Team | ANZUP Cancer Trials Group |
Scheme | Investigator-initiated research project |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2020 |
GNo | |
Type Of Funding | External |
Category | EXTE |
UON | N |
UNISoN; Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab In Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602; CA209-718)$1,681,800
In this clinical trial ANZUP will test whether new immune treatments can help people with rare kidney cancer (‘non-clear cell’ cancer). Non-clear cell represents approximately 25% of people with kidney cancer; and because it is rare there are no treatments currently reimbursed in Australia.
The UNISoN trial will test immune treatments in two different ways; firstly we will find out how well one immune treatment (nivolumab) works alone. If this is unhelpful by itself, then people can continue taking nivolumab but also add in a 2nd immune treatment (ipilimumab). We will discover how many people will benefit from one drug alone, and by doing detailed laboratory testing of people’s cancer samples, hope to also learn who will only benefit from taking both treatments together.
Nivolumab and ipilimumab have been used alone or together in many cancers, so the side-effects are well known and should be manageable. Immune treatments help some people with cancer, especially those with melanoma, common (clear cell) kidney cancer, lung and bladder cancer. Unfortunately they are much less effective in other cancers (like pancreas, prostate and brain cancers). Nivolumab and ipilimumab have not been tested in people with non-clear cell kidney cancers, so ANZUP is delighted to ask this question, and hope to help people with this rare disease.
Funding body: BMS Australia
Funding body | BMS Australia |
---|---|
Project Team | ANZUP Cancer Trials Group |
Scheme | Investigator initiated research project |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | External |
Category | EXTE |
UON | N |
2:1 Randomised Phase II Study of NivolUmab and Temozolomide vs Temozolomide in Methylated newly diagnosed Elderly Glioblastoma (NUTMEG) ASSOCIATE INVESTIGATOR$1,608,845
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Khasraw M, Rosenthal M, McDonald K, Ashley D. |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | N |
20162 grants / $1,753,049
Start-Up activities with or without a pilot and definitive randomised double-blind placebo-controlled trial of oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting$1,750,000
Does cannabis help people taking chemotherapy? There is anecdotal evidence but this clinical trial will provide a definitive answer.
Introduction Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Trials using delta-9-tetrahydrocannabinol-rich (THC) products demonstrate limited antiemetic effect, significant adverse events and flawed study design. Trials using cannabidiol-rich (CBD) products demonstrate improved efficacy and psychological adverse event profile. No definitive trials have been conducted to support the use of cannabinoids for this indication, nor has the potential economic impact of incorporating such regimens into the Australian healthcare system been established. CannabisCINV aims to assess the efficacy, safety and cost-effectiveness of adding TN-TC11M, an oral THC/CBD extract to guideline-consistent antiemetics in the secondary prevention of CINV.
Methods and analysis The current multicentre, 1:1 randomised cross-over, placebo-controlled pilot study will recruit 80 adult patients with any malignancy, experiencing CINV during moderate to highly emetogenic chemotherapy despite guideline-consistent antiemetics. Patients receive oral TN-TC11M (THC 2.5mg/CBD 2.5 mg) capsules or placebo capsules three times a day on day −1 to day 5 of cycle A of chemotherapy, followed by the alternative drug regimen during cycle B of chemotherapy and the preferred drug regimen during cycle C. The primary endpoint is the proportion of subjects attaining a complete response to CINV. Secondary and tertiary endpoints include regimen tolerability, impact on quality of life and health system resource use. The primary assessment tool is patient diaries, which are filled from day −1 to day 5. A subsequent randomised placebo-controlled parallel phase III trial will recruit a further 250 patients.
Funding body: NSW Health
Funding body | NSW Health |
---|---|
Project Team | Grimison P, Haber P, Stockler M, Lintzeris N, Simes R, McGregor I, Olver I, Allsop D, Gedye C, Kirby A |
Scheme | Health Administration Corporation , NSW |
Role | Investigator |
Funding Start | 2016 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | N |
Bringing CLARITY to Brain Cancer$3,049
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Dr JAMIE Flynn, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2016 |
Funding Finish | 2016 |
GNo | G1600967 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
20155 grants / $687,675
Advanced Technical Support for Oncology Single Cell Analysis Technologies$300,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Rodney Scott, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Craig Gedye, Professor Pradeep Tanwar, Doctor Chen Chen Jiang, Professor Matt Dun, Professor Paul de Souza, Associate Professor Kevin Spring, Dr Tao Liu |
Scheme | Research Infrastructure Grants |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2018 |
GNo | G1500824 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$300,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Marjorie Walker, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Emeritus Professor John Forbes, Professor Xu Dong Zhang, Professor Pradeep Tanwar, Professor Nikola Bowden, Doctor Craig Gedye, Doctor James Lynam, Associate Professor Kelly Kiejda, Doctor Jennette Sakoff, Mr Loui Rassam, Dr Tara Roberts, Professor Soon Lee, Dr Betty Kan |
Scheme | Research Infrastructure Grants |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2018 |
GNo | G1500825 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
Destroying kidney cells that evade current treatments$46,000
Funding body: Kidney Health Australia
Funding body | Kidney Health Australia |
---|---|
Project Team | Doctor Craig Gedye, Professor Nikola Bowden, Professor Rodney Scott |
Scheme | Medical Research Project Grants |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1401048 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
BAALC - a novel target for the development of new treatments for brain cancer.$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1600225 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Too Much of a Good Thing: Application for a triple-gas incubator to allow cell culture under normal conditions$16,675
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Craig Gedye, Professor Rodney Scott, Professor Nikola Bowden, Professor Simon Keely, Associate Professor Kathryn Skelding |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1500730 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20143 grants / $787,065
The Virtuous Circle: A Living Brain Cancer BioBank$331,393
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Rodney Scott, Doctor Craig Gedye, Professor Marjorie Walker |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2018 |
GNo | G1401406 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
High Throughput Image Capture Platform for Translational Cancer Research$282,614
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Conjoint Professor Stephen Ackland, Professor Rodney Scott, Emeritus Professor John Forbes, Professor Xu Dong Zhang, Professor Marjorie Walker, Professor Hubert Hondermarck, Doctor Craig Gedye, Doctor Rick Thorne, Mr Loui Rassam, Doctor Stephen Braye |
Scheme | Research Equipment Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1400626 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
Is Renal Cell Carcinoma Driven by "Cancer Stem Cells"?$173,058
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Craig Gedye |
Scheme | Training (Postdoctoral) Fellowships - C.J. Martin Biomedical Fellowships (Overseas) |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2015 |
GNo | G1400027 |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | Y |
1 grants / $265,000
Embedding patient tissue banking consent into routine clinical practice: To maximize state-wide consent and enable a patient-led approach to tissue banking$265,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Rodney Scott, Doctor Craig Gedye, Professor Christine Paul, Assoc. Prof Nicholas Hawkins, Associate Professor Deborah Marsh, Professor Phil Crowe |
Scheme | Community of Practice Program |
Role | Investigator |
Funding Start | |
Funding Finish | |
GNo | G1400792 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2021 | PhD | ER Stress as a Diagnostic Biomarker and Therapeutic Target in Glioblastoma | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Past Supervision
Year | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2020 | PhD | The Precursor for Nerve Growth Factor and Innervation in Thyroid Cancer | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Research Collaborations
The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.
Country | Count of Publications | |
---|---|---|
Australia | 132 | |
Canada | 46 | |
United States | 42 | |
France | 28 | |
United Kingdom | 25 | |
More... |
News
News • 9 Jul 2021
Cancer research gets $7 million boost in NSW regions
People living with cancer and the healthcare professionals caring for them are the winners from a $7 million investment, announced by NSW Regional Health Partners on Friday.
News • 25 May 2017
Study using new tools to unlock secrets of immune cells in cancer
An in-depth atlas of the tumour microenvironment has been mapped by an international cancer team involving Hunter researcher Dr Craig Gedye, seeking to build a clearer picture of how the immune system is involved with cancer.
News • 13 Oct 2015
Expanding the horizons of brain cancer research
A raft of Mark Hughes Foundation (MHF) travel grants will give Hunter brain cancer researchers the chance to build new clinical trial collaborations at the international COGNO Annual Scientific Meeting in Brisbane this month.
News • 16 Feb 2015
More flexibility needed in melanoma treatment
Survival rates would be improved by making treatment regimens for metastatic melanoma more flexible, according to HMRI cancer researcher Dr Craig Gedye, a medical oncologist at the Calvary Mater Newcastle.
News • 29 Oct 2014
Brain cancer biobank
A new "biobank" for brain cancer is being established at the Hunter Medical Research Institute courtesy of funding from the Mark Hughes Foundation (MHF).
Dr Craig Gedye
Position
Conjoint Associate Professor
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Contact Details
craig.gedye@newcastle.edu.au |